Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

Rhea-AI Summary

Xeris Biopharma (XERS) reported strong financial results for Q4 and full-year 2024, with record quarterly revenue of $60M (35% growth) and annual revenue of $203M (24% growth). Key product performance includes:

- Gvoke® Q4 revenue: $23.3M (+25% YoY), with 35% market share
- Recorlev® Q4 revenue: $22.6M (+131% YoY)
- Keveyis® Q4 revenue: $11.1M (-21% YoY)

The company ended Q4 with $71.6M in cash, generating $2M in cash flow and $8.3M in Adjusted EBITDA for the quarter. For 2025, Xeris projects total revenue guidance of $255M-$275M, representing over 30% growth at the mid-point.

Positive

• Record Q4 revenue of $60M (+35% YoY)
• Annual revenue reached $203M (+24% YoY)
• Recorlev revenue more than doubled (+131% YoY)
• Positive Q4 cash flow of $2M
• Strong 2025 revenue guidance of $255M-$275M
• Q4 Adjusted EBITDA of $8.3M

Negative

• Keveyis revenue declined 21% YoY in Q4
• Net loss of $54.8M for full-year 2024
• SG&A expenses increased 12% YoY
• R&D expenses increased 14% YoY

Insights

Financial Analyst

Xeris Biopharma's Q4 and full-year 2024 results represent a significant financial inflection point for the company. The reported $60M quarterly revenue (up 35% YoY) and $203M annual revenue (up 24% YoY) demonstrate robust commercial execution. More importantly, the company has now achieved positive cash flow generation ($2M in Q4) and positive Adjusted EBITDA of $8.3M for the quarter, marking the transition to operational profitability.

The product portfolio shows Recorlev emerging as the primary growth driver, with Q4 revenue up 131% YoY to $22.6M and sequential growth of 28%. This powerful performance effectively offsets the 21% YoY decline in Keveyis revenue. Meanwhile, Gvoke maintains healthy growth with a 25% YoY revenue increase and 35% market share.

Management's 2025 guidance of $255M-$275M (representing >30% growth at midpoint) coupled with projections for sustained positive Adjusted EBITDA indicates strong confidence in the commercial trajectory. While the company still posted a net loss of $5.1M for Q4 and $54.8M for full-year 2024, the positive Adjusted EBITDA and cash flow generation suggest the underlying business fundamentals are strengthening considerably.

The solid cash position of $71.6M provides operational flexibility for continued commercial execution without immediate financing pressure. This financial transformation marks a critical milestone in Xeris' evolution toward sustainable profitability.

Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year

Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially

Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter

Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range

Hosting conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full-year ended December 31, 2024 and provides full-year 2025 financial guidance.

“The Xeris team executed an exceptional 2024 with record revenue topping $203 million,” said John Shannon, Xeris’ Chief Executive Officer. “The continued momentum of our commercial business, our exciting pipeline, along with our unrelenting focus on execution will enable Xeris to create even more value for patients and shareholders.”

“Xeris has never been financially stronger. Record quarterly revenue exceeding $60 million drove positive cash flow of $2 million in the fourth quarter and generated Adjusted EBITDA of over $8 million,” said Steven M. Pieper, Chief Financial Officer. “We expect 2025 total revenue of $255 to $275 million, which is over 30% growth at the mid-point. Further, we anticipate Adjusted EBITDA will remain positive going forward. Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris.”

Fourth Quarter 2024 Highlights
	Three months ended December 31,						Change
	2024			2023			$			%
Product revenue (in thousands):
Gvoke	$	23,262		$	18,639		$	4,623		24.8
Recorlev		22,614			9,806			12,808		130.6
Keveyis		11,124			14,064			(2,940	)	(20.9	)
Product revenue, net		57,000			42,509			14,491		34.1
Royalty, contract and other revenue		3,099			1,881			1,218		64.8
Total revenue	$	60,099		$	44,390		$	15,709		35.4

• Gvoke®: Fourth quarter net revenue was $23.3 million – an increase of approximately 25% compared to the fourth quarter of 2023. Gvoke prescriptions grew 18% compared to the same period in 2023. Gvoke’s share of the retail prescriptions glucagon market averaged 35% in the fourth quarter.
• Recorlev®: Fourth quarter net revenue was $22.6 million – an increase of approximately 131% compared to the fourth quarter of 2023. This growth was driven by the average number of patients on Recorlev increasing 123% from the same period in 2023. On a sequential basis, Recorlev net revenue increased $4.9 million or 28% versus the prior quarter.
• Keveyis®: Fourth quarter net revenue was $11.1 million – a decrease of approximately 21% compared to the fourth quarter of 2023. This decrease was primarily driven by a reduction in product shipments in the period.
• Royalty, contract and other revenue: In the fourth quarter, we successfully formulated a unique XeriSol® formulation of glucagon for Beta Bionics, Inc., resulting in the recognition of $3.0 million in revenue.

Year-to-Date 2024 Financial Results
	Years Ended December 31,						Change
	2024			2023			$			%
Product revenue (in thousands):
Gvoke	$	82,829		$	67,045		$	15,784		23.5
Recorlev		64,277			29,547			34,730		117.5
Keveyis		49,530			56,772			(7,242	)	(12.8	)
Product revenue, net		196,636			153,364			43,272		28.2
Royalty, contract and other revenue		6,434			10,550			(4,116	)	(39.0	)
Total revenue	$	203,070		$	163,914		$	39,156		23.9

• Gvoke®: Net revenue was $82.8 million for the year ended December 31, 2024 – an increase of approximately 24% compared to prior year. Gvoke prescriptions for the year were approximately 265,000, growing approximately 23% compared to the same period in 2023.
• Recorlev®: Net revenue was $64.3 million for the year ended December 31, 2024 – an increase of approximately 118% compared to prior year. This growth was driven by an increase in the number of patients on therapy.
• Keveyis®: Net revenue was $49.5 million for the year ended December 31, 2024 – a decrease of approximately 13% compared to prior year. This decrease was primarily driven by a reduction of average patients on therapy.

Cost of goods sold (COGS) increased $1.9 million or 25% in the fourth quarter 2024 compared to the same period in 2023. This increase was primarily due to an increase in product revenue.

For the year-end December 31, 2024, COGS increased $8.2 million or 29% compared to the same period in 2023. This increase was due to increased product revenue ($4.9 million) and additional inventory reserves from process changes required for Gvoke capacity expansion ($4.5 million), offset by lower reserves for slow-moving inventory.

Research and development (R&D) expenses was relatively flat in the fourth quarter 2024 compared to the same period last year. Expenses in the quarter supported our pipeline, notably XP-8121, and personnel related expenses to support our pipeline and continued investment in our technology platforms and partnerships.

R&D expenses for the year ended December 31, 2024 increased by $3.2 million or 14% compared to the same period in 2023. This increase was primarily due to higher personnel related expense and increased spending for our pipeline.

Selling, general and administrative (SG&A) expenses increased $2.6 million or 7% in the fourth quarter 2024 compared to the same period last year. This increase was primarily due to incremental investment in the Recorlev commercial organization.

SG&A expenses increased by $17.4 million or 12% for the year ended December 31, 2024 compared to the same period in 2023. This increase was due to personnel related expense ($13.5 million), primarily due to investments made in the Recorlev commercial organization in Q4 2023 and Q3 2024, and the CEO succession plan and related restructuring in Q3 2024 ($6.1 million), partially offset by lower external spend.

Net Loss for the fourth quarter was $5.1 million or ($0.03) per share and $54.8 million or ($0.37) per share for the year-ended December 31, 2024.

Adjusted EBITDA¹ for the fourth quarter was $8.3 million and $1.2 million for the year-end December 31, 2024.

Cash, cash equivalents, and short-term investments at December 31, 2024 was $71.6 million, compared to $72.5 million at December 31, 2023. Total shares outstanding at February 28, 2025 was 153,940,135.

Conference Call and Webcast Details

Xeris will host a conference call and webcast at 8:30 a.m. Eastern Time today to discuss the Company's financial and operational results. To pre-register for the conference call, please use the following link: https://www.netroadshow.com/events/login?show=ecd4fc1e&confId=76382

After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, March 20, 2025 at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 694296.

To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link:

Note Regarding Use of Non-GAAP Financial Measures

This press release includes financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP) and also certain historical and forward-looking non-GAAP financial measures, namely Adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation and should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP, and was not prepared under any comprehensive set of accounting rules or principles. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP, and the calculation of the non-GAAP financial measure included herein may differ from similarly titled measures used by other companies. The Company believes that the presentation of Adjusted EBITDA, when viewed in conjunction with actual GAAP results, provides investors with a more meaningful understanding of our ongoing and projected operating performance, exclusive of factors that do not directly affect what the Company considers to be its core operating performance, as well as unusual events. We believe this non-GAAP financial measure helps indicate underlying trends in the Company’s business and is important in comparing current results with prior period results and understanding expected operating performance. Also, management uses this non-GAAP financial measure to establish budgets and operational goals, and to manage the Company’s business and evaluate its performance. In addition, management believes that Adjusted EBIDTA is important in evaluating the administrative costs of operating the Company’s business.

Adjusted EBITDA is GAAP net income (loss) before income tax (benefit) expense, plus interest and other income, less depreciation and amortization, interest expenses, share based compensation, debt refinancing fees and loss on debt extinguishment relating to the exchange in September 2023 of $32.0 million in aggregate principal of 5.00% Convertible Senior Notes due 2025 for $33.6 million in aggregate principal amount of new 8.00% Convertible Senior Notes due 2028.

We are unable to reconcile our forward-looking guidance for Adjusted EBITDA to its most directly comparable GAAP measure. This is because the company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain components of such GAAP metric and reconciliations due to market-related assumptions such as information regarding future compensation charges, future changes in the market price of our common stock or other costs which may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.

About Xeris

Xeris (Nasdaq: XERS) is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram.

Forward-Looking Statements

Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding guidance for 2025, including the potential for revenue growth and Adjusted EBIDTA, the potential for 2025 to be financially transformative, our ability to drive more value for patients and shareholders, the market and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, its and collaborators’ ability to protect its intellectual property and proprietary technology, and general macroeconomic conditions. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including its most recently filed Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

¹ Adjusted EBITDA is a non-GAAP financial measure. See "Note Regarding Use of Non-GAAP Financial Measures" and the corresponding financial tables at the end of this press release for definitions and reconciliations of non-GAAP measures.

XERIS BIOPHARMA HOLDINGS, INC.  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
	Three Months Ended December 31,								Years Ended December 31,
	2024				2023				2024				2023
	(unaudited)				(unaudited)
Product revenue, net	$	57,000			$	42,509			$	196,636			$	153,364
Royalty, contract and other revenue		3,099				1,881				6,434				10,550
Total revenue		60,099				44,390				203,070				163,914
Costs and expenses:
Cost of goods sold		9,478				7,570				36,832				28,645
Research and development		6,092				6,382				25,560				22,341
Selling, general and administrative		40,139				37,568				163,481				146,095
Amortization of intangible assets		2,711				2,711				10,843				10,843
Total costs and expenses		58,420				54,231				236,716				207,924
Loss from operations		1,679				(9,841	)			(33,646	)			(44,010	)
Other expenses		(6,792	)			(3,785	)			(23,458	)			(19,494	)
Net loss before benefit from income taxes		(5,113	)			(13,626	)			(57,104	)			(63,504	)
Benefit from income taxes		—				236				2,268				1,249
Net loss	$	(5,113	)		$	(13,390	)		$	(54,836	)		$	(62,255	)
Net loss per common share - basic and diluted	$	(0.03	)		$	(0.10	)		$	(0.37	)		$	(0.45	)
Weighted average common shares outstanding - basic and diluted		149,092,881				138,124,878				146,772,758				137,674,857

XERIS BIOPHARMA HOLDINGS, INC.  Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA
(in thousands, unaudited)
	Three Months Ended December 31,								Years Ended December 31,
	2024				2023				2024				2023
GAAP Net Loss	$	(5,113	)		$	(13,390	)		$	(54,836	)		$	(62,255	)
Adjustments
Interest and other income		(910	)			(1,107	)			(5,321	)			(4,751	)
Interest expense		7,703				7,018				30,485				26,609
Income tax (benefit) expense		—				(236	)			(2,268	)			(1,249	)
Depreciation and amortization		3,024				3,057				12,070				12,330
EBITDA		4,704				(4,658	)			(19,870	)			(29,316	)
Adjustments
Share-based compensation (a)		3,595				2,767				18,363				10,716
Debt refinancing fees (b)		—				—				2,690				—
Loss on debt extinguishment, net (b)		—				—				—				2,837
Adjusted EBITDA		8,299				(1,891	)			1,183				(15,763	)

(a) Includes non-cash, stock-based compensation, net of forfeitures.

(b) Represents non-recurring fees related to financing activities. Including (1) debt refinancing fees which related to advisory and legal fees to refinance the term loan in 2024 and (2) loss on debt extinguishment related to the exchange in September 2023 of $32.0 million in aggregate principal of 5.00% Convertible Senior Notes due 2025 for $33.6 million in aggregate principal amount of new 8.00% Convertible Senior Notes due 2028.

XERIS BIOPHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
	December 31, 2024				December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	71,621			$	67,449
Short-term investments		—				5,002
Trade accounts receivable, net		40,415				39,197
Inventory		48,175				38,838
Prepaid expenses and other current assets		7,451				5,778
Total current assets		167,662				156,264
Property and equipment, net		5,562				5,971
Intangible assets, net		98,921				109,764
Goodwill		22,859				22,859
Operating lease right-of-use assets		22,649				23,204
Other assets		5,407				4,540
Total assets	$	323,060			$	322,602
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	2,290			$	11,565
Current portion of long-term debt		15,102				—
Current operating lease liabilities		6,080				3,495
Other accrued liabilities		27,716				23,510
Accrued trade discounts and rebates		29,084				22,149
Accrued returns reserve		19,082				14,198
Current portion of contingent value rights		—				19,109
Other current liabilities		1,089				1,167
Total current liabilities		100,443				95,193
Long-term debt, net of unamortized debt issuance costs		217,006				190,932
Non-current contingent value rights		—				1,379
Non-current operating lease liabilities		33,259				34,764
Deferred tax liabilities		—				2,268
Other liabilities		1,967				4,848
Total liabilities		352,675				329,384
Total stockholders’ equity (deficit)		(29,615	)			(6,782	)
Total liabilities and stockholders’ equity (deficit)	$	323,060			$	322,602

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250306430605/en/

Investor Contact

Allison Wey

Senior Vice President, Investor Relations and Corporate Communications

awey@xerispharma.com

Source: Xeris Biopharma Holdings, Inc.

FAQ

What was Xeris Biopharma's (XERS) revenue growth in Q4 2024?

XERS achieved record quarterly revenue of $60M in Q4 2024, representing 35% growth compared to Q4 2023.

How much revenue growth does Xeris (XERS) expect for 2025?

Xeris projects 2025 revenue of $255M-$275M, representing over 30% growth at the mid-point of the range.

What was Recorlev's performance for Xeris (XERS) in Q4 2024?

Recorlev Q4 revenue was $22.6M, growing 131% YoY and 28% sequentially from Q3 2024.

How much cash does Xeris Biopharma (XERS) have as of Q4 2024?

Xeris ended Q4 2024 with $71.6M in cash, generating $2M in cash flow during the quarter.

What was Xeris Biopharma's (XERS) Adjusted EBITDA for Q4 2024?

XERS reported Q4 2024 Adjusted EBITDA of $8.3M and $1.2M for the full year 2024.